News | Radiation Oncology | October 24, 2023

Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in the Journal of Clinical Oncology and accepted by ESMO for oral presentation 

Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in the Journal of Clinical Oncology and accepted by ESMO for oral presentation

Lunit AI-powered TIL analyzer, Lunit Scope 10


October 24, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC) with resistance to certain targeted therapies. 

A groundbreaking study, conducted by Samsung Medical Center and utilizing Lunit SCOPE IO, showcases the efficacy of atezolizumab plus bevacizumab and chemotherapy for NSCLC patients with EGFR or ALK mutations. The study result was concurrently published in the Journal of Clinical Oncology (JCO; IF 50.739) and presented in an oral presentation at the ESMO (European Society of Medical Oncology) 2023 Annual Meeting. Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO. 

This research marks a turning point for NSCLC patients with EGFR or ALK mutations, as prior trials faced challenges in identifying effective treatments. Patients with these mutations often respond favorably to targeted agents, but over time, the effectiveness of these treatments diminishes. Multiple leading pharmaceutical companies have attempted clinical trials of immunotherapy in this setting, which have not succeeded to date. This underscores the significance of this first successful phase III trial in this setting, successfully combining immunotherapy with chemotherapy and improving clinical outcomes. 

The study enrolled a total of 228 NSCLC patients with activating EGFR mutation (215 patients) or ALK translocation (13 patients), who experienced progression after the relevant tyrosine kinase inhibitor (TKI) therapy. Patients were randomized into two arms: the ABCP arm (atezolizumab plus bevacizumab/paclitaxel/carboplatin) and the PC arm (pemetrexed plus carboplatin or cisplatin). The results demonstrated the superiority of the ABCP arm, with significantly higher objective response rates (ORR; 69.5% vs. 41.9%) and a longer median progression-free survival (PFS; 8.48 months vs. 5.62 months). 

Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research. By assessing patients' immune phenotype and predicting response to immunotherapy, Lunit SCOPE IO enabled the identification of individuals more likely to benefit from ABCP arm treatment. In the group with an Inflamed Score below 20%, there was no significant difference in PFS between ABCP arm and PC arm (8.28 months vs. 6.93 months). However, a substantial difference in PFS was observed in the group with an Inflamed Score of 20% or higher (12.91 months vs. 4.86 months), surpassing the overall study group. Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment. 

For more information: www.lunit.com


Related Content

News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Artificial Intelligence

February 29, 2024 — AIxSCAN, Inc., a Sunnyvale, CA-based developer of a next generation artificial intelligence (AI) ...

Time February 29, 2024
arrow
News | Women's Health

February 27, 2024 — Hologic, Inc. continues to deliver on its commitment to advancing women’s health by unveiling new ...

Time February 27, 2024
arrow
Feature | HIMSS | Christine Book

February 26, 2024 — This year’s Healthcare Information and Management Systems Society HIMSS Global Conference and ...

Time February 23, 2024
arrow
News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
Feature | HIMSS | By Christine Book

February 22, 2024 — With just weeks to go before HIMSS 2024, the Global Conference and Exhibition of the Healthcare ...

Time February 22, 2024
arrow
News | Artificial Intelligence

February 22, 2024 — Hartford HealthCare has announced the unveiling of its Center for AI Innovation in Healthcare ...

Time February 21, 2024
arrow
Videos | Information Technology

Industry trade shows and conferences seem to be making their comeback in 2024. And the Healthcare Information and ...

Time February 21, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
Sponsored Content | Videos | Digital Radiography (DR)

Agfa Radiology Solutions is committed to enhancing clinical outcomes and operational efficiency, underscoring its ...

Time February 12, 2024
arrow
Subscribe Now